Orphenadrine Citrate

ApprovedSmall molecule

UUniversity of Baghdad

Orphenadrine Citrate is one of 14 small molecule programs targeting Bruxism. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BruxismActive, not recruiting

BruxismApproved

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Bruxism

#DrugCompanyPhaseTrials

Botox

RRevance Therapeutics, Inc.

Approved

2 2

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

2 3

XEOMIN

MMerz Pharmaceuticals GmbH

Paraflex

1 5

Xeomin

MMerz Therapeutics GmbH

Phase 3

1 6

Orphenadrine Citrate

UUniversity of Baghdad

Approved

1 7

Dysport

GGalderma R&D

Preclinical

1 8

Botox

AbbVie

Preclinical

2 9

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Preclinical

2 10

Pharmacotherapy

UUniversity of Pittsburgh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bruxism1 trial

Effectiveness of Chlorzoxazone Versus Orphenadrine Citrate in Alleviating Bruxism Pain

Recruiting·UUniversity of Baghdad·Phase 4·NCT07109882·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Orphenadrine Citrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Orphenadrine Citrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Orphenadrine Citrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Baghdad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Baghdad

Orphenadrine Citrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bruxism1 trial

References

Drug Info

Quick Facts

Related News